title: Mean Platelet Volume in Crohn's Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot Study.
abstract: BACKGROUND
  The loss of response to infliximab in Crohn's disease (CD) patients is currently a major clinical problem. Recently, mean platelet volume (MPV) has been proposed as a new biomarker of CD activity. Here, we hypothesized that MPV may be used as cheap and efficient biomarker of subclinical inflammation during 52-week therapy in CD patients responding to infliximab induction treatment.
  
  
  OBJECTIVE
  The aim of study was to establish whether MPV at baseline and pre-infusion at week 14 are good predictors of sustained response after week 14 in CD patients undergoing 52-week infliximab therapy.
  
  
  METHODS
  A retrospective study of 30 adult CD patients who underwent a 52-week course of treatment with infliximab and achieved response at week 14 to induction treatment was performed. The association between MPV, baseline disease parameters and maintained clinical response or remission during infliximab therapy was assessed.
  
  
  RESULTS
  Higher MPV at week 14 was observed in CD patients with sustained response to infliximab after week 14 than in patients with loss of response (p = 0.0019). In patients with loss of response to maintenance infliximab treatment, lower ΔMPV between baseline and week 14 was calculated (p = 0.0003). MPV > 10.3 fl at week 14 predicts sustained response with 67 % sensitivity and 80 % specificity. ΔMPV between baseline and week 14 >0.4 fl predicts sustained response with 87 % sensitivity and 93 % specificity.
  
  
  CONCLUSIONS
  MPV at week 14 and ΔMPV between baseline and week 14 are good predictors of sustained response to infliximab maintenance treatment in CD patients.
authors.affiliation: Department of Gastroenterology, Medical University of Lodz, Haller Sq. 1, 90-647, Lodz, Poland.
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Sobolewska
authors.affiliation: Department of Gastroenterology, Medical University of Lodz, Haller Sq. 1, 90-647, Lodz, Poland. dr.mwlodarczyk@gmail.com.
authors.forename: Marcin
authors.identifier: http://orcid.org/0000-0001-9118-4623
authors.initials: M
authors.lastname: Włodarczyk
authors.affiliation: Department of Gastroenterology, Medical University of Lodz, Haller Sq. 1, 90-647, Lodz, Poland.
authors.forename: Krystyna
authors.initials: K
authors.lastname: Stec-Michalska
authors.affiliation: Department of Biochemistry, Medical University of Lodz, Lodz, Poland.
authors.forename: Jakub
authors.initials: J
authors.lastname: Fichna
authors.affiliation: Department of Gastroenterology, Medical University of Lodz, Haller Sq. 1, 90-647, Lodz, Poland.
authors.forename: Maria
authors.initials: M
authors.lastname: Wiśniewska-Jarosińska
mesh_terms: D000328:Adult; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D008297:Male; D063847:Mean Platelet Volume; D011237:Predictive Value of Tests; D012189:Retrospective Studies
chemical_list: D005765:Gastrointestinal Agents; D000069285:Infliximab
keywords: Crohn’s disease; Infliximab; Mean platelet volume; Prognosis; Treatment outcomes